YOKOHAMA, Japan--(BUSINESS WIRE)--ReproCELL, Inc. (JASDAQ:4978):
“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year. Read on for details.
Our company, in conjunction with the National Cancer Center, has successfully developed and commercialized a culture fluid that allows for the cultivation of human primary liver cells, outside of the body, while retaining high levels of functionality. The preservation of liver functions (CYP: enzymatic functions involved in counteraction and metabolism in livers) outside of the body has been technically difficult until now. Rethinking the composition of culture fluids from scratch, our product allows for a preservation of liver functionality many times greater than products previously available.
